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Local control of early-stage primary lung cancer is a main-stay of treatment. Surgical resection of primary lung
cancer is the current standard of care for patients with stage
I non-small cell lung cancer (NSCLC) if they are able to
tolerate an adequate surgical procedure for this disease. Most
patients with stage I disease will achieve long-term survival
after surgical resection, provided their survival is not limited
by other comorbid conditions. The results of conventional
radiation therapy have generally not provided local control
rates as high as those for surgery for stage I NSCLC, most
likely because of the limitation of delivery of an optimal dose
and volume to control the primary tumor. Furthermore, most
patients with stage I NSCLC treated by conventional radio-
therapy had medical contraindication for undergoing surgery.
Therefore, their local control rates were not adequately as-
sessed because of their short-term survival and the inability of
imaging studies to assess primary tumor control because of
lung fibrosis after radiotherapy. Stereotactic body radiation
therapy (SBRT) has been used extensively for small brain
tumors in which immobilization allows precise delivery of a
high dose of radiation to control tumors without damaging
surrounding normal tissue. Recent advances with three-di-
mensional conformal techniques can now compensate for
lung motion and allow delivery of high single fractions to the
primary lung tumor for patients with clinical stage I NSCLC.
The contributors to this supplement have been pioneers in
applying this technology to the treatment of lung cancer.
Several series of patients with clinical stage I lung
cancer, including patients with both medically inoperable and
potentially surgically resectable tumors, treated with SBRT
have been reported from the United States and Japan. Both
local control rates and 5-year survival seem to be comparable
to that reported in surgical series. There are ongoing phase II
clinical trials in both the United States (Radiation Therapy
Oncology Group) and Japan (Japan Clinical Oncology
Group) to evaluate SBRT for the treatment of potentially
resectable stage I NSCLC.
Current data are provocative and raise the possibility
that early-stage lung cancer could be treated primarily with
SBRT. This question assumes even greater importance be-
cause of the increasing numbers of early-stage lung cancers
identified by computed tomography screening techniques,
with many of these lesions in the centimeter or subcentimeter
range. We cannot ignore these technical advances in imaging
of early lung cancer and imaging-guided radiation treatment
planning combined with immobilization techniques that per-
mit precise treatment followed by an accurate assessment of
the primary tumor control by computed tomography and
positron emission tomography. Recommendation for such a
significant change in primary treatment should occur only on
the basis of the highest level of clinical trial evidence.
This was the rationale for holding a workshop titled
“Development of an International Cooperative Clinical Trial
Comparing Stereotactic Radiation Therapy with Surgery for
Stage I NSCLC” on February 17 to 19, 2007, in Maui,
Hawaii. The purpose of the workshop was to develop an
international cooperative clinical trial with radiation oncolo-
gists, thoracic surgeons, medical oncologists, and biostatisti-
cians from the United States, Japan, and China. All aspects of
protocol design were discussed, including eligibility, treat-
ment strategies, and adjuvant chemotherapy. There were
smaller breakout groups to work on specific aspects of the
protocol design. Speakers reviewed the experience with ste-
reotactic radiation therapy and surgery in treating stage I
NSCLC in North America and Japan.
Discussion focused on resolving the scientific issues
and logistical challenges needed for a successful clinical trial.
The conference was successful, and a clinical protocol has
been prepared. The completion of this clinical trial will be
complex and challenging. Clearly an international effort will
be required to accrue a sufficient number of patients. Rigor-
ous quality control and certification procedures will be nec-
essary to ensure high technical standards and uniformity
among a large number of institutions. However, it is imper-
ative that this new technology be evaluated in a phase III
clinical trial compared with surgery, the current standard of
care, so that the role of this emerging technology in the care
of patients with stage I lung cancer can be defined with
certainty and patients can benefit from this novel treatment.
The organizers would like to thank the International
Association for the Study of Lung Cancer (IASLC) for their
support of this international conference and for facilitating
the international effort to develop a clinical trial.
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